Table 2: Case series and retrospective studies reported in literature.
|
Author |
Year |
Study type |
N. patients |
Mean age (range) |
Only breast |
N+ (%) |
M1 (%) |
ER+ |
PR+ |
Her2+ |
CrA+ |
Syn+ |
Mast |
BCS |
No surgery |
Adj RT |
Adj CHT |
Adj OT |
Mean FUP (range) |
|
Papotti[122] |
1992 |
CS* |
4 |
56 (41-64) |
25,00% |
75,00% |
50,00% |
NA |
NA |
NA |
NA |
NA |
100,00% |
0,00% |
0,00% |
25,00% |
25,00% |
25,00% |
20,5(9-44) |
|
Shin[123] |
2000 |
CS* |
9 |
55,4 (43-70) |
44,44% |
55,56% |
0,00% |
66,67% |
55,56% |
0,00% |
44,44% |
44,44% |
33,33% |
66,67% |
0,00% |
44,44% |
77,78% |
0,00% |
20,3(3-35) |
|
Zekioglu[124] |
2003 |
CS** |
12 |
65,0 (43-49) |
91,67% |
8,33% |
0,00% |
91,67% |
91,67% |
16,67% |
41,67% |
91,67% |
50,00% |
50,00% |
0,00% |
NA |
NA |
NA |
24,1(1-54) |
|
Bonet[125] |
2008 |
CS** |
7 |
61,3 (35-88) |
57,14% |
42,86% |
NA |
100,00% |
100,00% |
14,29% |
0% |
100% |
71,43% |
14,29% |
14,29% |
28,57% |
28,57% |
100,00% |
51,64(2, 7-115,5) |
|
Tian[126] |
2011 |
Ret** |
74 |
61 (29-82) |
52,70% |
41,89% |
8,11% |
95,00% |
80,00% |
9,00% |
NA |
NA |
40,54% |
57,81% |
17,27% |
NA |
NA |
NA |
46,92 (0-260) |
|
Kanat[127] |
2011 |
CS** |
7 |
43,8 (29-56) |
14,29% |
85,71% |
28,57% |
28,57% |
28,57% |
0,00% |
57,14% |
100% |
85,71% |
14,29% |
0,00% |
71,43% |
85,71% |
28,57% |
22,4(9-48) |
|
Kawasaki[128] |
2011 |
Ret** |
27 |
47,8 (28-74) |
95,83% |
4,17% |
0,00% |
100,00% |
100,00% |
54,17% |
NA |
NA |
37,50% |
62,50% |
0,00% |
NA |
NA |
NA |
83,7 (64-101) |
|
Zhang[129] |
2013 |
Ret** |
107 |
65 (25-95) |
NA |
NA |
NA |
94,39% |
85,05% |
2,80% |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
27† (3-134) |
|
Wu[130] |
2012 |
Ret** |
13 |
55,4 (36-78) |
92,31% |
7,69% |
7,69% |
100,00% |
100,00% |
0,00% |
69,23% |
30,77% |
100,00% |
0,00% |
0,00% |
NA |
NA |
100,00% |
67,5 (41-89) |
|
Rovera[131] |
2013 |
Ret** |
96 |
70,1 (40-94) |
NA |
NA |
NA |
90,00% |
75,00% |
1,04% |
NA |
NA |
30,21% |
31,25% |
36,46% |
48,00% |
5,00% |
75,00% |
88† (4-242) |
|
Zhu[132] |
2013 |
Ret** |
22 |
52,5 (29-77) |
NA |
NA |
NA |
90,91% |
95,00% |
25,00% |
95,00% |
14,29% |
68,18% |
31,82% |
0,00% |
0,00% |
63,64% |
90,91% |
64,5 (4-89) |
|
Charfi[133] |
2013 |
Ret*** |
15 |
62,3 (37-78) |
73,33% |
26,67% |
0,00% |
80,00% |
93,33% |
0,00% |
73,33% |
6,67% |
80,00% |
20,00% |
0,00% |
86,67% |
46,67% |
60,00% |
40,14 (3-125) |
|
Cloyd[134] |
2014 |
Ret*** |
284 |
NA |
43,40% |
36,20% |
20,40% |
46,5% |
35,6% |
NA |
NA |
NA |
35,20% |
36,60% |
27,80% |
41,50% |
NA |
NA |
NA |
|
Jeon[135] |
2014 |
Ret*** |
11 |
54,7 (29-79) |
NA |
NA |
NA |
100,00% |
100,00% |
0,00% |
54,55% |
0,00% |
36,36% |
63,64% |
0.00% |
NA |
NA |
NA |
38,6 (21-76) |
|
Roininen[136] |
2017 |
Ret*** |
43 |
66 (NA) |
55,8% |
39,53% |
9,3% |
97,70% |
86,10% |
4,70% |
69,80% |
0,00% |
58,20% |
39,60% |
2,27% |
74,40% |
34,09% |
75,00% |
NA |
Headings: Ret = retrospective; CS = Case Series;
*Previous to 2003 criteria, ** According to 2003 criteria, *** According to WHO 2012 criteria
†Median follow-up